24 articles
Chemours Company faces a securities class action lawsuit alleging misleading statements regarding Opteon aftermarket demand by executives. Eligible investors purchasing shares during the specified per
A securities fraud class action has been filed against Chemours following an 18.63% stock drop linked to alleged misrepresentations of Opteon product demand. Investors have until December 7, 2026, to
Robbins LLP is soliciting Chemours shareholders for a class action lawsuit alleging overstated Opteon demand caused unreliable 2026 guidance and a significant stock price decline.
A law firm filed a class action against Chemours, alleging overstated demand for its Opteon products led to unreliable financial guidance. Investors buying securities during the specified period are u
SueWallSt.com notifies Chemours investors of a December 7, 2026 deadline for a class action lawsuit alleging misleading statements on Opteon refrigerant demand and 2026 financial guidance.
Chemours Co faces a securities class action lawsuit alleging fraud over overstated Opteon product demand and unreliable 2026 financial guidance. Investors are being encouraged to seek recovery for los
Robbins LLP urges Chemours investors with losses between February and August 2026 to contact the firm regarding a class action lawsuit alleging overstated Opteon demand led to unreliable financial gui
Levi & Korsinsky LLP filed a securities class action against Chemours Co., alleging misleading statements on Opteon demand and EBITDA guidance between February and August 2026. Investors with losses d
Moore Law PLLC is investigating Chemours after an 18.63% stock drop and guidance cut linked to excess Opteon inventory and lowered EBITDA outlook.
Chemours Co. faces a securities class action alleging overstated Opteon demand and poor financial guidance caused a stock drop. Investors may join the suit before the December 7, 2026 deadline.
A securities class action lawsuit has been filed against Chemours Co. alleging overstated Opteon product demand caused financial losses. Investors have until December 7, 2026, to join as lead plaintif
A class action lawsuit was filed against Chemours Co alleging false statements regarding Opteon product demand and unreliable financial guidance for 2026.
Investors in Chemours Co may lead a class action lawsuit alleging the company overstated demand for Opteon refrigerants and issued unrealistic guidance, leading to an 18.63% stock decline.
Portnoy Law Firm filed a class action against Chemours Co., alleging misleading disclosures on Opteon inventory and AIM Act transition impacts caused stock drops. The suit follows reduced financial ou
Faruqi & Faruqi LLP reminds Chemours investors of the December 7, 2026, deadline for a securities class action lawsuit alleging false statements about Opteon product demand.
Levi & Korsinsky, LLP filed a securities class action against The Chemours Company alleging overstated demand for Opteon products led to unreliable financial guidance. Investors must apply for lead pl
Robbins LLP reminds investors of a securities class action lawsuit against The Chemours Company alleging overstated demand for Opteon products and unreliable 2026 financial guidance. Investors may fil
Chemours faces a class action lawsuit over alleged overstated Opteon demand and lowered 2026 guidance, following a 19% stock decline due to oversupplied inventory channels.
Chemours Co faces a securities class action lawsuit concerning Opteon demand and 2026 financial guidance disclosures. While investors view the stock as undervalued at $13.61 versus an $18.56 fair valu
A securities fraud class action lawsuit alleges Chemours made misleading statements regarding Opteon product demand, causing a stock drop. Investors have until December 7, 2026, to file lead plaintiff
The Law Offices of Frank R. Cruz filed a class action against Chemours alleging misleading statements on Opteon product demand and 2026 guidance, resulting in an 18.63% stock decline.
Chemours Q2 sales fell 1% to $1.591 billion amid lower Opteon refrigerant demand, though adjusted net profit reached $64 million meeting analyst expectations with free cash flow up 128%.
Chemours maintained its 2026 outlook despite lower aftermarket refrigerant sales, reporting flat Q2 net sales of $1.591 billion. Adjusted EBITDA in its Thermal & Specialized Solutions segment rose 3%,
Chemours Co declared a quarterly cash dividend of $0.0875 per share for the third quarter of 2026, payable on September 15, 2026. The global industrial and specialty chemicals leader continues its sha
ChemBrief